<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00526409</url>
  </required_header>
  <id_info>
    <org_study_id>LAL-AR-N-2005</org_study_id>
    <nct_id>NCT00526409</nct_id>
  </id_info>
  <brief_title>LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia</brief_title>
  <acronym>LAL-AR-N-2005</acronym>
  <official_title>LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to improve the global results obtained with LAL-AR-93 study, reaching&#xD;
      an event free survival between 60-70%.&#xD;
&#xD;
      Identify patients with bad prognosis, with minimal residual disease,who can benefit of&#xD;
      allogenic bone marrow transplantation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INDUCTION TREATMENT&#xD;
&#xD;
      Systemic chemotherapy:&#xD;
&#xD;
      PREDNISOLONE 60 mg/m2 /day, oral or i.v. x 21 days (1 to 22) 30 mg/m2 /day, oral or i.v. x 7&#xD;
      days (23 to 29)&#xD;
&#xD;
      DAUNORUBICIN 30 mg/m2 , i.v. days 1,8,15 and 22&#xD;
&#xD;
      VINCRISTINE 1,5 mg/m2, i.v. days 1,8,15 and 22&#xD;
&#xD;
      L-ASPARAGINASE 10.000U/m2 i.m or i.v day 9,11,13,16,18,20,23,25 and 27&#xD;
&#xD;
      CYCLOPHOSPHAMIDE 500 mg/m2 i.v. days 1,2 and 29&#xD;
&#xD;
      Intrathecal chemotherapy:&#xD;
&#xD;
      Days 1 and 22 according age:&#xD;
&#xD;
      Age &lt;1 years 1-3 years &gt;3 years&#xD;
&#xD;
      Methotrexate (MTX), mg 5 8 12 Ara-C, mg 16 20 30 Hydrocortisone,mg 10 10 20&#xD;
&#xD;
      Patients with &lt;10% blasts in M.O (day 14), and in complete response on week 5 or 6, and&#xD;
      without MDR, start consolidation-intensification phase.&#xD;
&#xD;
      Patients with &gt;10% blasts in MO day +14 or without CR after induction treatment, start&#xD;
      consolidation-intensification phase and identifier a donor for a transplantation.&#xD;
&#xD;
      CONSOLIDATION/INTENSIFICATION (C.I.)&#xD;
&#xD;
      Two sequential cycles, alternating bloc I and bloc II&#xD;
&#xD;
      BLOC I&#xD;
&#xD;
      DEXAMETHASONE 10 mg/m2/d vo. days 1 to 5 and 5 mg/m2/d vo. days 6 and 7&#xD;
&#xD;
      VINCRISTINE 1.5 mg/m2/d, i.v. days 1 and 8&#xD;
&#xD;
      METHOTREXATE 5 g/m2 24 hours infusion + AF, day 1&#xD;
&#xD;
      ARA-C 1 g/m2/12 h, i.v., days 5 and 6&#xD;
&#xD;
      MERCAPTOPURINE 100 mg/m2/d, oral, days 1 to 5&#xD;
&#xD;
      CYCLOPHOSPHAMIDE 500 mg/m2 i.v. el day +8&#xD;
&#xD;
      INTRATHECAL CHEMOTHERAPY day 1.&#xD;
&#xD;
      BLOC II&#xD;
&#xD;
      DEXAMETHASONE 10 mg/m2/d, v o. days 1-5 and 5 mg/m2/d, v o. days 6 and 7&#xD;
&#xD;
      VINCRISTINE 1.5 mg/m2/d, days 1 and 8&#xD;
&#xD;
      METHOTREXATE 5 g/m2 24 h infusion + AF, day 1&#xD;
&#xD;
      ARA-C 1 g/m2 i.v/12 h, days 5 and 6&#xD;
&#xD;
      DAUNORUBICINE 30 mg/m2 i.v.day 1&#xD;
&#xD;
      L-ASPARAGINASE 20.000 u/m2/d, i.m. or i.v. day 7&#xD;
&#xD;
      INTRATHECAL CHEMOTHERAPY day 1&#xD;
&#xD;
      Patients with CR and MRD negative, follow chemotherapy. Patients with MDR &gt;0.01% after second&#xD;
      cycle or considered previously MRD are candidates to allogenic transplantation after second&#xD;
      cycle.&#xD;
&#xD;
      REINDUCTION/INTENSIFICATION TREATMENT (R.I.)&#xD;
&#xD;
      PREDNISOLONE 60 mg/m2/d, oral x 14 days (1-14) 30 mg/m2/d, oral x 7 days (15-22)&#xD;
&#xD;
      VINCRISTINE 1.5 mg/m2, i.v. x 2 days 1 and 8&#xD;
&#xD;
      DAUNORUBICINE 30 mg/m2 i.v x 2 , days 1 and 8&#xD;
&#xD;
      CYCLOPHOSPHAMIDE 500 mg/m2 I.V. day 15&#xD;
&#xD;
      -----------------------------------------&#xD;
&#xD;
      METHOTREXATE 3 g/m2 /24 h infusion + AF day 29&#xD;
&#xD;
      MERCAPTOPURINE 50 mg/m2/d, oral, days 29-35 and 43-50&#xD;
&#xD;
      ARA-C 1 g/m2/12 h., i.v., days 43 and 44&#xD;
&#xD;
      INTRATHECAL CHEMOTHERAPY , days 1, 15, 29 and 43&#xD;
&#xD;
      MAINTENANACE TREATMENT (M1)&#xD;
&#xD;
      Six cycles of:&#xD;
&#xD;
      MERCAPTOPURINE 50 mg/m2/d, oral x 21 days (1-21)&#xD;
&#xD;
      METHOTREXATE 20 mg/m2/d, i.m. /week x 3 (1,7,14)&#xD;
&#xD;
      PREDNISOLONE 60 mg/m2/d, oral x 7 days (22-28)&#xD;
&#xD;
      VINCRISTINE 1.5 mg/m2 i.v.day 22&#xD;
&#xD;
      ASPARAGINASE 20.000 u/m2 i.m. day 22&#xD;
&#xD;
      INTRATHECAL CHEMOTHERAPY day 22&#xD;
&#xD;
      MAINTENANCE TREATMENT (M2)&#xD;
&#xD;
      Diary mercaptopurine and weekly methotrexate at previous doses, until complete 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To improve the global results obtained in PETHEMA LAL-AR-93 study in terms of events free time</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Induction: 60 mg/m2/day, oral or i.v x 21 days and 30 mg/m2/day oral or iv x 7 days Reinduction-Intensification Treatment: 60 mg/m2/d x 14 days and 30 mg/m2/day oral x 7 days</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Induction: 30 mg/m2, i.v, days 1, 8, 15, 22 Consolidation (Bloc II)30 mg/m2, i.v, day 1</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Induction: 1,5 mg/m2 iv, days 1, 8, 15, 22 Consolidation (Bloc I):1,5 mg/m2 iv, days 1, 8 Consolidation (Bloc II):1,5 mg/m2 iv, days 1, 8 Reinduction: 1,5 mg/m2 iv, days 1, 8 Maintenance:1,5 mg/m2 iv, day 22</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Asparaginase</intervention_name>
    <description>Induction: 10.000 U/m2 im or iv, days 9,11,13,16,18,20,23,25,27 Consolidation (Bloc II): 20.000 U/m2 im or iv, day 7 Maintenance: 20.000 U/m2 im or iv, day 22</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Induction: 500 mg/m2 iv, days 1, 2, 29 Consolidation (Bloc I): 500 mg/m2 iv, day 8 Reinduction:500 mg/m2 iv, day 15</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Consolidation (Bloc I): 5 g/m2 24 hours infusion Consolidation (Bloc II): 5 g/m2 24 hours infusion Reinduction: 3 g/m2 24 hours infusion Maintenance: 20 mg/m2/d, IM/week x 3 (1, 7, 14)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytosine Arabinoside</intervention_name>
    <description>Consolidation (Bloc I): 1 g/m2/12 h iv, days 5, 6 Consolidation (Bloc II): 1 g/m2/12 h iv, days 5, 6 Reinduction: 1 g/m2/12 h iv, days 43, 44</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  High risk children with acute lymphoblastic leukemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mature B-ALL (FABL3)&#xD;
&#xD;
          -  Mixed forms of ALL&#xD;
&#xD;
          -  Patients with coronary disorders, valvular or hypertensive cardiopathy&#xD;
&#xD;
          -  Patients with chronic liver disorders&#xD;
&#xD;
          -  Chronic pulmonary disorders&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Neurologic disfunctions&#xD;
&#xD;
          -  ECOG 3 and 4&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bastida Pilar, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitari Materno-Infantil Vall d'Hebron</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ribera Josep Mª, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital materno Infantil vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Niño Jesús</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.aehh.org</url>
    <description>Spanish association of Haematology</description>
  </link>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>September 6, 2007</study_first_submitted>
  <study_first_submitted_qc>September 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <last_update_submitted>October 27, 2014</last_update_submitted>
  <last_update_submitted_qc>October 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

